Financial Data and Key Metrics Changes - Third quarter revenue totaled $223 million, an increase of nearly 8% from the previous year, with organic revenue growth of 4.7% [7][20] - Adjusted EBITDA for the quarter was $52.4 million, up 14.7% year-over-year, with margin expansion contributing to the increase [8][21] - Adjusted free cash flow for the third quarter was $18 million, contributing to a year-to-date total of $53 million, leading to an increase in adjusted free cash flow guidance for 2025 to between $100 million and $115 million [8][25] - Adjusted EPS was $0.12 per share, a 50% increase compared to the same quarter last year [21] Business Line Data and Key Metrics Changes - The nuclear and safety segment revenue grew 9% to $144.6 million, with organic growth of 4.4% [23] - The medical segment revenue totaled $78.5 million, up 5.9%, with organic revenue growth of 5.2% [24] - Adjusted orders in the nuclear power end market grew 21%, reflecting strong demand across new builds, SMRs, and the installed base [10][16] Market Data and Key Metrics Changes - Year-to-date orders in the U.S. nuclear power end market increased by 44%, primarily driven by SMR activity [16] - The global nuclear fleet's average capacity factor reached 83% in 2024, indicating potential for increased operational efficiency [11] - The IAEA has raised its nuclear capacity forecast, expecting nearly a terawatt of nuclear capacity by 2050 [11] Company Strategy and Development Direction - The company is focused on broadening its nuclear power portfolio through acquisitions, including the recent Paragon Energy Solutions deal [6][14] - The strategy includes enhancing software solutions for regulatory compliance and expanding the U.S. presence with additional products and services [13][14] - The company aims to capitalize on the nuclear renaissance and is optimistic about the growth potential in the nuclear power sector [5][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the nuclear power market's growth, citing strong order flow and favorable trends in SMR orders [9][10] - The medical segment is expected to normalize despite current pressures, with continued demand driven by aging populations and increased cancer incidence [35][37] - Management remains optimistic about achieving a level of equilibrium in the U.S. healthcare environment, which has been impacted by budgetary constraints [71][72] Other Important Information - The company expects to maintain a blended cost of debt of 2.8% into 2026, reflecting a significant improvement over the past year [8] - The company has a robust opportunity pipeline, with $285 million still to be awarded, of which $175 million is expected to be awarded by year-end [19][42] Q&A Session Summary Question: Regarding the commercial nuclear backlog and potential acceleration - Management indicated that the installed base and new utility scale builds are key drivers for future backlog growth, with government support expected to streamline project timelines [31][32] Question: Insights on the medical business amidst current pressures - Management remains positive about the medical business, citing strong demand drivers and expecting normalization in the RTQA segment [35][37] Question: Confidence in the $175 million pipeline and potential awards - Management expressed confidence in the pipeline, noting that timing is unpredictable but they feel they have a strong right to win on these opportunities [42] Question: Discussion on SMR opportunities and related projects - Management highlighted the expanding SMR opportunity set, with over 120 projects in development and significant government support aiding market evolution [46][62] Question: Pricing power trends in nuclear safety versus medical - Management noted that pricing power remains strong, particularly in the nuclear segment, while being more cautious in the medical segment due to current market conditions [68] Question: U.S. healthcare environment impacts on business - Management explained that Medicaid cuts and overall market noise have created a defensive CapEx environment, but they expect demand dynamics to normalize [71][72]

Financial Data and Key Metrics Changes - Third quarter revenue totaled $223 million, an increase of nearly 8% from the previous year, with organic revenue growth of 4.7% [6][19] - Adjusted EBITDA for the quarter was $52.4 million, up 14.7% year-over-year, with margin expansion contributing to the increase [7][20] - Adjusted free cash flow for the third quarter was $18 million, contributing to a year-to-date total of $53 million, leading to an increase in adjusted free cash flow guidance for 2025 to between $100 million and $115 million [7][24] - Adjusted EPS was $0.12 per share, a 50% increase compared to the same quarter last year [20] Business Line Data and Key Metrics Changes - Nuclear and safety segment revenue grew 9% to $144.6 million, with organic growth of 4.4% [22] - Medical segment revenue totaled $78.5 million, up 5.9%, with organic revenue growth of 5.2% [23] - Adjusted orders in the nuclear power end market grew 21%, reflecting strong demand across new builds, SMRs, and the installed base [9][15] Market Data and Key Metrics Changes - Year-to-date orders in the U.S. nuclear power end market increased by 44%, primarily driven by SMR activity [15] - The global nuclear fleet's average capacity factor reached 83% in 2024, indicating a positive trend for nuclear power utilization [10] - The IAEA has increased its nuclear capacity forecast, expecting nearly a terawatt of nuclear capacity by 2050 [10] Company Strategy and Development Direction - The company is focused on expanding its nuclear power portfolio through acquisitions, including the recent Paragon Energy Solutions deal [5][12] - The strategy includes enhancing software solutions for regulatory compliance and broadening product offerings in the nuclear power sector [12][13] - The company remains optimistic about the nuclear renaissance and its positioning to benefit from it [5][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the nuclear power market's growth, citing strong order flow and government support for new projects [31][32] - The medical segment is expected to normalize despite current pressures, with continued demand for cancer care solutions [36][71] - Management anticipates a rebound in the RTQA business as funding dynamics stabilize [36] Other Important Information - The company expects to close the Paragon acquisition by year-end, which will enhance its U.S. presence and product offerings [5][12] - The company is actively managing supply chain risks and has developed strategies to mitigate exposure to critical commodities [65][66] Q&A Session Summary Question: Regarding the commercial nuclear backlog and project activity - Management indicated that the installed base and new utility scale builds are key drivers for future backlog growth, with government support expected to streamline project timelines [30][31] Question: Insights on the medical business amidst current pressures - Management remains optimistic about the medical segment, citing strong demand drivers and expecting normalization in the RTQA business [34][36] Question: Confidence in the $175 million pipeline and potential awards - Management expressed confidence in the pipeline, noting that timing for large opportunities can be unpredictable but remains optimistic about winning a significant portion [41] Question: Clarification on SMR opportunities and project details - Management highlighted the expanding SMR project pipeline and the importance of government support in accelerating market growth [44][61] Question: Pricing power trends in nuclear safety versus medical - Management noted positive pricing dynamics in the nuclear segment, while being more cautious in the medical segment due to current market conditions [68] Question: Impact of U.S. healthcare environment on business - Management discussed the effects of Medicaid cuts and overall market noise on capital expenditures, but remains confident in the underlying demand for their solutions [71]

Core Insights - Vaso Corporation's shares have declined 4.3% since the earnings report for Q2 2025, underperforming the S&P 500 Index, which lost 1.1% during the same period [1] - The company reported a revenue decrease of 1.3% year-over-year, resulting in a net loss of $0.2 million compared to a net income of $1.2 million in the previous year [2] Revenue Breakdown - Professional sales services revenue fell 4% to $8.7 million, primarily due to lower diagnostic imaging equipment deliveries from GE HealthCare [3] - The IT segment saw a slight increase of 0.9% to $10.7 million, driven by stronger network services, while the equipment segment remained nearly flat at $0.5 million, up 0.8% [3] Profitability Metrics - Gross profit decreased by 2.9% to $11.8 million, with a margin of 59%, down from 60% a year ago [4] - Selling, general and administrative (SG&A) expenses surged 11.2% to $12.1 million, contributing to an operating loss of $0.4 million compared to an operating income of $0.9 million in the prior year [5] Cash Flow and EBITDA - Adjusted EBITDA fell to a loss of $0.3 million from a positive $1.2 million in the previous year, while cash flow from operations improved to $6.2 million from $1.7 million [6] Management Commentary - Management attributed revenue decline to fewer GE HealthCare imaging equipment deliveries, with deferred commission revenue increasing to $38.1 million from $31.7 million [7] - Monthly recurring revenue in the IT segment represented 89% of segment revenues, up from 83% in the prior year [7] Operating Expenses - Operating expenses rose 9.5% to $12.2 million, mainly due to higher salesforce compensation and investor relations costs [8] Factors Influencing Performance - The quarterly loss was driven by contracting gross profit and rising SG&A expenses, with IT division margins narrowing due to a shift towards lower-margin network services [9] - Interest income decreased due to lower interest rates, although tax expenses declined, partially offsetting losses [10] Future Outlook - Vaso did not provide formal guidance for the remainder of 2025 but expressed confidence in ongoing IT recurring revenues and a strong deferred revenue balance [11] - The company remains bound by its sales representation agreement with GE HealthCare through 2026 and drew a short-term loan in China to support working capital needs [12]

Financial Data and Key Metrics Changes - In Q2 2025, total revenue increased by 16% sequentially to $7.1 million compared to $6.1 million in Q1 2025 [17] - Adjusted EBITDA for Q2 2025 was $1.7 million, up from $949,000 in Q1 2025 [11][21] - Net loss for Q2 2025 was $280,000, an improvement from a net loss of $625,000 in Q1 2025 [21] Business Line Data and Key Metrics Changes - Revenue from the Direct Patient Services segment was $3.5 million in Q2 2025, a 12% increase from $3.1 million in Q2 2024 [18] - Revenue from the equipment leasing segment decreased to $3.6 million from $3.9 million in Q2 2024 [18] - Gamma Knife revenue increased by 25% from Q1 2025 to $2.6 million in Q2 2025, but was down about 5% compared to Q2 2024 [19] Market Data and Key Metrics Changes - The company continues to see growth in international markets, particularly with the Gamma Knife centers in Peru and Ecuador, and the new center in Puebla, Mexico [13] - The acquisition of Rhode Island cancer treatment centers has significantly contributed to revenue growth [10][12] Company Strategy and Development Direction - The company is transitioning from a cancer treatment equipment leasing focus to a more patient-centric service model, which is expected to drive long-term growth [6][7] - Plans to expand operations include building a fourth radiation therapy treatment center in Bristol, Rhode Island, and a proton beam radiation therapy center [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth trajectory, emphasizing the importance of focusing on overall growth opportunities [8][16] - The company anticipates fluctuations in treatment volumes but remains optimistic about steady growth in the overall business [11][16] Other Important Information - The company ended Q2 2025 with cash and cash equivalents of $11.3 million, consistent with the end of 2024 [25] - Shareholders' equity was $24.5 million, down from $25.2 million at the end of 2024 [26] Q&A Session Summary Question: Are there any pre-opening activities for the new locations in Rhode Island? - Management confirmed the addition of three full-time radiation oncologists to support the new centers, which will enhance service delivery [30][31] Question: Will these activities benefit the new centers? - Management affirmed that there are economies of scale with the expansion within the Rhode Island marketplace [33]

Core Viewpoint - American Shared Hospital Services reported a 16% sequential increase in total revenue for Q2 2025, driven by growth in treatment volumes and expansion of services [2][5]. Financial Performance - Q2 2025 revenue reached $7,071,000, a 0.2% increase compared to Q2 2024, attributed to expanded radiation therapy services [6]. - Revenue from direct patient services was $3,500,000, an 11% increase year-over-year, primarily due to acquisitions in Rhode Island and the new facility in Puebla, Mexico [6]. - The medical equipment leasing segment saw an 8% decrease in revenue to $3,571,000, impacted by lower Gamma Knife volumes and the expiration of customer contracts [7]. - Proton beam radiation therapy revenue decreased to $1,921,000 from $2,420,000 in the prior year, reflecting cyclical fluctuations [7]. Treatment Volume and Revenue Breakdown - Radiation therapy revenue for Q2 2025 was $2,541,000, up from $1,892,000 in Q2 2024, driven by the Rhode Island centers and Puebla operations [8]. - Gamma Knife revenue increased by 25% sequentially but decreased by 5% compared to Q2 2024 [5]. - LINAC revenue grew by 7% sequentially and 34% year-over-year [5]. - Proton beam radiation therapy revenue increased by 17% sequentially but decreased by 21% compared to Q2 2024 [5]. Profitability and Loss - The company reported a net loss of $280,000 or $0.04 per share for Q2 2025, compared to a net income of $3,602,000 or $0.55 per diluted share in Q2 2024 [9]. - Adjusted EBITDA for Q2 2025 was $1,701,000, down from $2,010,000 in Q2 2024 [9]. Long-term Growth Strategy - The CEO emphasized a focus on expanding the business model and operational enhancements, with expectations for growth from new installations in Mexico and recent approvals for new treatment centers in Rhode Island [4]. - The company has experienced four consecutive years of revenue growth and three years of sustained profitability, with ongoing strategic acquisitions to bolster growth potential [4]. Balance Sheet Highlights - As of June 30, 2025, cash and cash equivalents totaled $11,331,000, slightly up from $11,275,000 at the end of 2024 [14]. - Shareholders' equity was $24,481,000 or $3.78 per share, down from $25,183,000 or $3.92 per share at the end of 2024 [14].

Core Insights - STERIS plc (STE) reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.34, reflecting a 15.3% increase year-over-year and surpassing the Zacks Consensus Estimate by 0.9% [1][10] - The company's GAAP EPS was $1.79, marking a 27% increase from the previous year's $1.41 [1] Revenue Performance - Total revenues from continuing operations reached $1.39 billion, an 8.6% year-over-year increase, although this figure missed the Zacks Consensus Estimate by 2.4% [3][10] - Organic revenues at constant exchange rate (CER) rose by 8% year-over-year [3] Segment Analysis - **Healthcare Segment**: Revenues increased by 8% year-over-year to $974.7 million, driven by a 5% rise in consumable revenues, a 13% increase in service revenues, and a 6% improvement in capital equipment revenues [4] - **Applied Sterilization Technologies (AST)**: Revenues improved by 13% to $281.2 million, with service revenues growing by 12% and capital equipment revenues surging by 46% [5] - **Life Sciences Segment**: Revenues increased by 5% to $135.2 million, supported by an 8% rise in consumable revenues [6] Margin and Expense Analysis - Gross profit for the quarter was $628 million, up 9.7% year-over-year, with a gross margin expansion of 41 basis points to 45.1% despite a 7.9% increase in the cost of revenues [7] - Selling, general and administrative expenses rose by 5.4% to $353.8 million, while research and development expenses increased by 3.1% to $26.4 million [8] Financial Position - Cash and cash equivalents at the end of the first quarter stood at $279.7 million, up from $171.7 million at the end of fiscal 2025 [11] - Net cash flow from operating activities was $420 million compared to $303.7 million in the previous year [12] Guidance - STERIS raised its fiscal 2026 revenue growth guidance to 8-9%, up from the previous 6-7% projection, with an adjusted EPS forecast of $9.90-$10.15 [10][13] - The Zacks Consensus Estimate for revenues is pegged at $5.83 billion, indicating a 6.8% growth from fiscal 2025 [13] Overall Assessment - The company ended the first quarter of fiscal 2026 positively, with both earnings and revenues exceeding estimates across all business segments [14]

Core Insights - STERIS plc reported a strong financial performance for the first quarter of fiscal 2026, with total revenue from continuing operations increasing by 9% to $1.4 billion compared to $1.3 billion in the same period last year [1][8] - The company experienced an adjusted net income of $231.2 million or $2.34 per diluted share, up from $201.7 million or $2.03 per diluted share in the previous year [2][8] Financial Performance - Total revenue from continuing operations increased by 9% to $1.4 billion, with constant currency organic revenue growth at 8% [1][9] - Net income from continuing operations was $177.4 million or $1.79 per diluted share, compared to $139.8 million or $1.41 per diluted share in the first quarter of fiscal 2025 [2][8] - Free cash flow for the first quarter was $326.5 million, an increase from $195.7 million in the prior year [6][10] Segment Performance - Healthcare revenue grew by 8% to $974.7 million, driven by a 13% increase in service revenue, 6% in capital equipment revenue, and 5% in consumable revenue [3][8] - Applied Sterilization Technologies (AST) revenue increased by 13% to $281.2 million, with a 46% rise in capital equipment revenue [4][8] - Life Sciences revenue rose by 5% to $135.2 million, supported by an 8% increase in consumable revenue [5][8] Outlook - The company updated its fiscal 2026 revenue outlook, now expecting an increase of 8-9% compared to previous expectations of 6-7% [9][10] - Adjusted earnings per diluted share are expected to remain in the range of $9.90 to $10.15, despite increased tariffs and higher employee healthcare costs [9][10] - Free cash flow is now anticipated to be approximately $820 million, up from prior expectations of $770 million [10] Board Changes - STERIS announced changes to its Board, with Dr. Jaqueline Kosecoff and Dr. Richard Steeves retiring, and Louis Shapiro being elected to the Board [7][9]

Core Insights - IBA has signed a contract with Steri-Tek to install a Be Wide X-ray Solution, enhancing Steri-Tek's sterilization capabilities [1][3] - The new system will increase Steri-Tek's processing capacity fivefold, allowing for the sterilization of full pallets and improving throughput [2][3] - The Be Wide X-ray Solution is expected to be operational by the end of 2027, with costs ranging from EUR 16 million to EUR 19 million [3] Company Overview - IBA is a leader in particle accelerator technology, specializing in proton therapy, industrial sterilization, and radiopharmaceuticals, employing approximately 2,100 people globally [6] - Steri-Tek is a high-volume E-beam/X-Ray contract sterilizer serving various industries, with facilities in California and Texas, and is certified in multiple quality standards [7]

Core Viewpoint - STERIS plc reported mixed results for the fourth quarter of fiscal 2025, with adjusted earnings per share (EPS) exceeding estimates while revenues fell short of expectations [13]. Financial Performance - Adjusted EPS for Q4 fiscal 2025 was $2.74, a 13.7% increase year-over-year, surpassing the Zacks Consensus Estimate by 5.8% [1] - GAAP EPS was $1.48, down 3.9% from $1.54 in the previous year [1] - Full-year adjusted EPS was $9.22, up 12.4% year-over-year, also exceeding the Zacks Consensus Estimate by 1.4% [2] Revenue Analysis - Q4 revenues from continuing operations were $1.48 billion, a 4.2% increase year-over-year, but missed the Zacks Consensus Estimate by 0.1% [3] - Organic revenues at constant exchange rate (CER) rose 6% year-over-year [3] - Full-year revenues from continuing operations reached $5.46 billion, a 6.2% increase year-over-year, matching the Zacks Consensus Estimate [3] Segment Performance - Healthcare segment revenues increased 5% year-over-year to $1.10 billion, with consumable revenues up 6% and service revenues up 13%, partially offset by a 4% decline in capital equipment revenues [4] - Applied Sterilization Technologies (AST) revenues improved 9% to $273.9 million, driven by 6% growth in service revenues [5] - Life Sciences segment revenues decreased 7% to $149.5 million, attributed to the divestiture of the CECS business, with consumable revenues growing 8% but capital equipment and service revenues declining significantly [6] Margin and Expense Insights - Gross profit for the quarter was $641.2 million, a 10% increase year-over-year, with gross margin expanding 224 basis points to 43.3% [7] - Selling, general and administrative expenses rose 8% to $333.9 million, while research and development expenses increased 0.8% to $27.7 million [8] - Adjusted operating expenses totaled $361.6 million, up 7.4% year-over-year, with adjusted operating margin expanding 153 basis points to 18.9% [8] Cash Flow and Guidance - Cash and cash equivalents at the end of fiscal 2025 were $171.7 million, down from $207 million at the end of fiscal 2024 [10] - Cumulative net cash flow from operating activities was $1.15 billion, compared to $973.2 million in the previous year [11] - For fiscal 2026, the company expects revenues from continuing operations to increase approximately 6-7%, with adjusted EPS projected in the range of $9.90-$10.15 [12]

Core Viewpoint - American Shared Hospital Services reported a 17% year-over-year revenue growth for Q1 2025, driven by strategic expansions and operational strengths despite some declines in treatment volumes [4][6]. Financial Performance - Revenue for Q1 2025 was $6.1 million, up from $5.2 million in Q1 2024, primarily due to expanded radiation therapy services [4][6]. - Direct patient services revenue surged by 224% to $3.1 million, attributed to the acquisition of Rhode Island centers and the new facility in Puebla, Mexico [4][6]. - Revenue from the medical equipment leasing segment decreased to $3.0 million from $4.3 million, influenced by lower Gamma Knife volumes and contract expirations [5][6]. Operational Highlights - The company experienced a gross margin of $942,000 in Q1 2025, down from $2.1 million in Q1 2024, mainly due to lower treatment volumes [7]. - A net loss of $625,000 was reported for Q1 2025, compared to a net income of $119,000 in the same period last year [7][16]. - Adjusted EBITDA for Q1 2025 was $0.9 million, a decrease from $1.7 million in Q1 2024 [8][18]. Strategic Initiatives - The company is optimistic about future growth, with plans for further acquisitions and operational efficiencies to enhance profitability [3][6]. - New facilities in Rhode Island and Mexico are expected to contribute to long-term growth, with a focus on expanding direct patient care services [3][4]. Balance Sheet Overview - As of March 31, 2025, cash and cash equivalents totaled $11.5 million, slightly up from $11.3 million at the end of 2024 [9][17]. - Shareholders' equity was reported at $24.6 million, down from $25.2 million at the end of the previous year [9][17].